2-47480707-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000233146.7(MSH2):c.2470C>T(p.Gln824Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. Q824Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
ENST00000233146.7 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.2470C>T | p.Gln824Ter | stop_gained | 15/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.2470C>T | p.Gln824Ter | stop_gained | 15/16 | 1 | NM_000251.3 | ENSP00000233146 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Aug 09, 2023 | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. - |
Lynch syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | research | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Sep 05, 2013 | Coding sequence variation introducing premature termination codon - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 16, 2020 | This nonsense variant causes the premature termination of MSH2 protein synthesis. In addition, it has been reported in individuals affected with Lynch syndrome in the published literature (PMID: 21778331 (2011), 14970868 (2004), 9506527 (1998)). Based on the available information, this variant is classified as pathogenic. - |
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 27, 2020 | This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln824*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. This variant has been observed in individuals affected with Lynch syndrome (PMID: 9506527, 21778331). ClinVar contains an entry for this variant (Variation ID: 90983). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 02, 2022 | The p.Q824* pathogenic mutation (also known as c.2470C>T), located in coding exon 15 of the MSH2 gene, results from a C to T substitution at nucleotide position 2470. This changes the amino acid from a glutamine to a stop codon within coding exon 15. This variant has been identified as somatic in conjunction with MSH2 copy neutral loss of heterozygosity (CN-LOH) in a tumor that demonstrated high microsatellite instability and loss of MSH2 and MSH6 expression by immunohistochemistry (IHC) (Ambry internal data). This variant has been reported in at least two Italian families with HNPCC, including an individual whose colorectal cancer demonstrated high microsatellite instability with loss of MSH2 and MSH6 expression by IHC (Genuardi M et al. Int. J. Cancer, 1998 Mar;75:835-9; Viel A et al. Community Genet, 1998;1:229-36; Capozzi E et al. Eur. J. Cancer, 1999 Feb;35:289-95; Ponz de Leon M et al. Br. J. Cancer, 2004 Feb;90:882-7). This variant has also been identified in a Spanish proband whose Lynch syndrome-associated tumor demonstrated loss of MSH2 and MSH6 expression by IHC (Pérez-Cabornero L et al. Cancer Prev Res (Phila), 2011 Oct;4:1546-55). Of note, this mutation is also designated as Q824X and p.Gln824X in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at